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Aims Heart failure with normal ejection fraction (HFnEF) is an important clinical entity that remains incompletely under-
stood. The novel biomarker growth differentiation factor 15 (GDF-15) is elevated in systolic heart failure (HFrEF) and
is predictive of an adverse outcome. We investigated the clinical relevance of GDF-15 plasma levels in HFnEF.
Methods
and results
A subgroup of patients from the ongoing DIAST-CHF observational trial, with a history of chronic heart failure (CHF)
or positive Framingham criteria at presentation, was selected. Patients were classiﬁed as having either HFrEF (n ¼ 86)
or HFnEF (n ¼ 142) and compared with healthy elderly controls (n ¼ 188) from the same cohort. Growth differen-
tiation factor 15 levels in HFnEF were signiﬁcantly higher than in controls and similar to those in HFrEF. In multivariate
analysis, factors signiﬁcantly associated with GDF-15 levels were age, sex, estimated glomerular ﬁltration rate (eGFR),
presence of HFrEF and HFnEF. Growth differentiation factor 15 correlated with multiple echocardiographic markers
of diastolic function and was associated with 6 min walk test performance and SF-36 physical score on multivariate
analysis in all patients. When using a classiﬁcation for HFnEF that did not employ N-terminal pro brain natriuretic
peptide (NT-proBNP) as a diagnostic criterion, the diagnostic properties of GDF-15 for detecting HFnEF tended
to be superior to those of NT-proBNP, and a combination signiﬁcantly improved diagnostic accuracy.
Conclusion Growth differentiation factor 15 is elevated in HFnEF to a similar degree as in HFrEF. It is independently associated
with impairment in exercise capacity and in physical components of quality of life. Diagnostic precision of GDF-15 is
at least as good as that of NT-proBNP and combining both markers improves diagnostic accuracy.
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Introduction
Chronic heart failure (CHF) is an ongoing epidemic of growing
dimensions.
1 Around 50% of patients with the clinical syndrome
of heart failure have a normal left ventricular ejection fraction
(LVEF).
2,3Thesecasesaretermed‘heartfailurewithnormalejection
fraction’ (or HFnEF) and left ventricular diastolic dysfunction is
believed to be the prominent aetiology.
4 Once hospitalized for
heart failure, the prognosis of HFnEF is as grim as systolic
heart failure (HFrEF).
2,3 Randomized trials in the search for speciﬁc
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doi:10.1093/eurjhf/hfq151therapeutic interventions have been few and notoriously
unsuccessful.
5,6
Biomarkers are increasingly used in CHF for diagnostic and prog-
nostic purposes. Some markers, e.g. natriuretic peptides, have been
introduced into clinical practice, but a growing number of novel
markers is under investigation.
7 Growth differentiation factor 15 is
a distant member of the TGF-ß superfamily. While it is not
expressed in normal hearts, increased expression of GDF-15 has
been demonstrated in animal models of dilative and hypertrophic
cardiomyopathy, in load-induced cardiac hypertrophy
8 and in
infarcted myocardium.
9 In these models, GDF-15 attenuated a
reduction in fractional shortening
8 and protected the heart from
cardiac hypertrophy
8 and ischaemia–reperfusion injury.
9 It has
been suggested to be a downstream marker indicative of different
myocardial stress pathways.
10 Promising data have led to a prop-
osition to use GDF-15 for risk stratiﬁcation in acute coronary syn-
dromes
11,13 or pulmonary embolism.
14 Growth differentiation
factor 15 is elevated and indicative of prognosis in HFrEF.
10,15
The aim of our study was to evaluate the clinical relevance of
GDF-15 plasma levels in an HFnEF population. We compared
this population with HFrEF patients and healthy elderly controls
from the same cohort.
Methods
Subjects
In the ongoing non-interventional DIAST-CHF trial, which is part of the
nationwide German Competence Network Heart Failure, 1935 partici-
pants aged 50–85 years were recruited in 2004 and 2005 with at least
one risk factor for HFnEF (deﬁned as history of hypertension, diabetes
mellitus, sleep apnoea syndrome or atherosclerotic disease) or estab-
lishedCHF.Participantswerereferredbyanetworkofprimarycarephys-
icians and inclusion criteria veriﬁed at the screening visit. As a
population-based trial, the only exclusion criteria were unwillingness to
participate or inability for logistic reasons. Participants underwent a com-
prehensivenon-invasivediagnosticworkupatbaseline,includingechocar-
diography. Diagnosis of CHF was made either based on the history or on
the presence ofat least one majorand two minor Framingham diagnostic
criteria
16 at presentation. Patients were classiﬁed retrospectively accord-
ing to echocardiographic measurements to have HFrEF when LVEF was
≤50%, or HFnEF when LVEF was .50% and diagnostic criteria for
HFnEF as recommended by the European Society of Cardiology
4 were
met. A group of apparently healthy elderly subjects were included in
DIAST-CHF as a reference group and followed the same procedures as
the main cohort. These subjects were used as controls for comparative
purposes and for assessing discriminatory properties of GDF-15 to
detect HFnEF. As it turned out that GDF-15 might be a valuable
marker for the presence of HFnEF, we used a second classiﬁcation for
HFnEF that did not employ N-terminal pro brain natriuretic peptide
(NT-proBNP) as a diagnostic criterion for comparative purposes: all
CHFpatientswithanLVEF .50%thatfulﬁlledechocardiographiccriteria
indicative of elevated ﬁlling pressures as recommended by the American
Society of Echocardiography (ASE)
17 were classiﬁed as HFnEFNew.F o r
clarity of presentation, we termed the conventionally classiﬁed group
HFnEFESC. While individual echocardiographic parameters used for
HFnEFESC and HFnEFNew classiﬁcation had been prospectively assessed
according to the study protocol at baseline except for retrograde A
wave duration in the pulmonary veins, ﬁnal classiﬁcation was performed
retrospectively for the purpose of this study.
DIAST-CHF complies with the Declaration of Helsinki, the protocol
was approved by the responsible ethics committee and all patients
gave written informed consent.
Procedures
All participants had their medical history, physical examination and an
ECG taken. In addition, a standardized 6-min walk test
18 was per-
formed. As a general estimate of quality of life, the widely used and
validated SF-36
19 was used. Blood samples were drawn after at least
15 min rest in the prone position for the analysis of routine laboratory
parameters and were stored at 2808C for later analysis. After thawing,
GDF-15 was measured in plasma with a pre-commercial electrochemi-
luminescence immunoassay and NT-proBNP with a commercially
available electrochemiluminescence immunoassay on an automated
Elecsys
w analyser (all Roche Diagnostics GmbH, Mannheim,
Germany) by an investigator blinded to patient characteristics.
Echocardiography was performed on a Hewlett-Packard Sonos
5500 (Hewlett-Packard, Andover, MA, USA) according to the guide-
lines of the ASE current at the time of data collection, including
measurement of peak velocities of early (E) and late (A) diastolic
mitral inﬂow and early (e ´) and late (a ´) tissue Doppler velocity waves
at the lateral mitral annulus, E wave deceleration time and peak systolic
(S) and diastolic (D) pulmonary vein ﬂow velocity. All examinations
were performed by physicians experienced in the technique. All indi-
vidual parameters used for the classiﬁcation and grading of diastolic
dysfunction were obtained successfully in .95% of patients. Randomly
chosen echo examinations were reviewed by the echo core laboratory
of the German Competence Network Heart Failure at the University
of Essen for quality assurance.
Calculations and statistical analyses
Left ventricular mass index (LVMI) was calculated by the Devereux
formula
20 indexed to body surface area. Left atrial volume index
(LAVI) was calculated by the ellipsoid model.
21 For evaluation of dias-
tolic function, we calculated the ratios E/A, E/e ´, e ´/a ´, and S/D. Diastolic
dysfunction was graded as follows: normal diastolic function (1 ≤E/A,
E/e ´ ,10, S/D ≥1, E/A with Valsalva manoeuvre ≥1), mild diastolic dys-
function (E/A ,1), moderate diastolic dysfunction (1≤ E/A ,2 and
one of the following: E/e ´ ≥10, S/D ,1, E/A Valsalva ,1), and
severe diastolic dysfunction (E/A ≥2 and one of the following: E/e ´
≥10, S/D ,1).
Descriptive statistics were performed stratiﬁed by group. Data are
expressed as median (interquartile range) for continuous variables.
Absolute numbers (percentage) are given for categorical variables.
Log-transformed values were used for some analyses as appropriate.
For non-parametric tests of differences between groups we used the
Kruskal–Wallis test for continuous variables and x
2 test for categorical
variables. Growth differentiation factor 15 levels were compared
across different grades of diastolic dysfunction by the non-parametric
Jonckheere–Terpstra test. To investigate relations between traits,
bivariate Pearsons correlation coefﬁcients were calculated. General
linear models with conditional inclusion of candidate variables were
used to unravel multivariate relationships. Receiver operating charac-
teristic (ROC) curves were constructed for discrimination between
controls and subjects with HFnEFESC or HFnEFNew and sensitivity,
speciﬁcity, and odds ratios HFnEF were calculated. The areas under
the curve (AUC) were compared by the method of Hanley and
McNeil.
22 P-values ,0.05 were considered signiﬁcant.
Statistical analyses were performed with PASW Statistics 18.0
software.
R. Stahrenberg et al. 1310Results
Of all patients with the clinical diagnosis of CHF, 86 had HFrEF and
142 HFnEFESC while 115 had an LVEF .50% but did not meet ESC
criteria for HFnEF. One hundred and eighty eight subjects were
included as healthy controls. Characteristics of the cohort are
shown in Table 1. Patients with HFrEF and HFnEFESC were compar-
able with regard to age, NT-proBNP and 6 min walk distance.
Patients with both HFrEF and HFnEFESC were older than controls.
Growth differentiation factor 15 was signiﬁcantly elevated in
HFnEFESC as compared with controls [1.66 (1.26; 2.34) vs. 0.90
(0.74; 1.09) ng/mL, P , 0.001] and was not signiﬁcantly different
from HFrEF [1.81 (1.37; 2.65) ng/mL] (Figure 1). 79.5% and 79.7%
of patients in HFrEF and HFnEFESC, respectively, had values
.1.20 ng/mL, which is the reported upper limit of normal,
15
while 14% of controls had values .1.20 ng/mL.
In the whole study sample, higher log(GDF-15) levels were
strongly associated with higher age, lower estimated glomerular ﬁl-
tration rate (eGFR), higher NT-proBNP, shorter 6 min walk distance
and lower SF-36 physical score, but also moderately with several
echocardiographic parameters indicative of systolic and diastolic
function (see Supplementary material online, Table S1). Prominent
among correlations with echocardiographic parameters of diastolic
function were those with increased LAVI, LVMI, E/e ´,d e c r e a s e de ´
and e ´/a ´. Jonckheere–Terpstra test unravelled signiﬁcantly increasing
GDF-15 levels across grades of diastolic dysfunction (P , 0.001,
Figure 2). As differing algorithms for grading the severity of
diastolic dysfunction have been used over the past years and
guidelines published in the meantime stress the relevance of E/e ´
values (with cut-offs that deviate from the one we used for
our grading scheme), Figure 3 additionally shows signiﬁcantly
increasing GDF-15 levels across three strata of E/e ´.F i n a l l y ,w e
observed a strong association with estimated right ventricular
systolic pressure.
When excluding patients with HFrEF, most correlations
remained signiﬁcant and retained their respective strength of
association. Interestingly, however, the associations with par-
ameters indicative of systolic function, i.e. LVEF and left ventricular
end-systolic and end-diastolic volume, were not signiﬁcantly associ-
ated with GDF-15 levels after exclusion of HFrEF. In contrast, the
association with E/e ´ appeared to be of a more continuous nature
(Figure 4).
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Table 1 Clinical characteristics
HFnEFESC HFrEF Controls P-value*
Age (years) 73 (66; 78) 71 (66; 75) 56 (52; 63)
# ,0.0005
Female gender 91 (64) 15 (17)
# 124 (66) ,0.0005
BMI (kg/m
2) 30.1 (26.7; 34.1) 29.1 (26.1; 32.7) 25.3 (22.9; 28.4)
# ,0.0005
Systolic blood pressure (mmHg) 147 (130; 164) 138 (122; 150)
# 127 (119; 137)
# ,0.0005
Diastolic blood pressure (mmHg) 80 (70; 90) 80 (70; 85) 78 (71; 85) 0.447
Heart rate (L/min) 66 (61; 74) 69 (62; 76) 73 (65; 79)
# ,0.0005
6 min walk distance (m) 431 (346; 500) 463 (400; 532) 584 (560; 604)
# ,0.0005
SF-36 physical function 50 (25; 70) 65 (35; 80)
# 90 (83; 100)
# ,0.0005
Diabetes mellitus (%) 43 (30) 32 (37) 0 (0)
# ,0.0005
Hypertension (%) 132 (93) 78 (91) 1 (1)
# ,0.0005
Hyperlipidaemia (%) 75 (53) 47 (55) 0(0)
# ,0.0005
Coronary artery disease (%) 49 (35) 45 (52)
# 0 (0)
# ,0.0005
Atrial ﬁbrillation (%) 35 (25) 23 (27) 1 (1)
# ,0.0005
ACE inhibitor (%) 69 (49) 58 (67)
# 1 (1)
# ,0.0005
AT1 receptor blocker (%) 41 (29) 16 (19) 0 (0)
# ,0.0005
Aldosterone antagonists (%) 7 (5) 12 (14)
# 0 (0)
# ,0.0005
b-Blocker (%) 87 (61) 64 (74) 1 (1)
# ,0.0005
Thiazide diuretic (%) 69 (49) 35 (41) 2 (1)
# ,0.0005
Loop diuretic (%) 51 (36) 41 (48) 0 (0)
# ,0.0005
Digitalis glycoside (%) 21 (15) 21 (24) 0 (0)
# ,0.0005
Statin (%) 57 (40) 41 (48) 0 (0)
# ,0.0005
Acetyl salicylic acid (%) 58 (41) 43 (50) 4 (2)
# ,0.0005
GDF-15 (ng/mL) 1.66 (1.26; 2.34) 1.81 (1.37; 2.65) 0.90 (0.7; 1.09)
# ,0.0005
NT-proBNP (ng/L) 326 (133; 634) 422 (148; 912) 63.9 (39.2; 112.0)
# ,0.0005
Estimated GFR (mL/min/1.73 m
2) 60 (49; 70) 61 (50; 76) 80 (71; 93)
# ,0.0005
LVEF (%) 60 (56; 65) 45 (36; 48)
# 61 (56; 66) ,0.0005
E/e ´ 11.6 (9.2; 14.5) 10.4 (7.6; 13.3) 6.9 (5.9; 8.5)
# ,0.0005
*P-value for difference across all groups by Kruskal–Wallis or x
2 test, as appropriate.
#P , 0.05 vs. HFnEFESC by Bonferroni-adjusted Mann–Whitney U or x
2 test, as appropriate.
GFD-15 in HFnEF 1311In a multivariate general linear model with log(GDF-15) as depen-
dent variable, higher age, male gender, lower eGFR, presence of
HFrEF and presence of HFnEF were identiﬁed as variables signiﬁ-
cantly predictive of higher GDF-15 levels, while body mass index
(BMI), systolic blood pressure, LVEF, E/e ´, LAVI, LVMI index and pres-
ence of coronary artery disease (CAD) did not add signiﬁcantly to
the model (adjusted r
2 ¼ 0.577 for overall model).
Because GDF-15 appeared to be strongly associated with 6 min
walk distance and SF-36 physical score, we used these parameters
as the respective dependent variable in general linear models.
Including BMI, age, gender, eGFR, CAD, HFrEF, HFnEF, E/e ´, LAVI,
LVMI, LVEF, and the common logarithms of GDF-15 and
NT-proBNP as covariates, GDF-15 remained signiﬁcantly (P ¼
0.01) and inversely associated with 6 min walk distance (adjusted
r
2 ¼ 0.524 for overall model). Similarly, the inverse association of
GDF-15 with SF-36 physical score just barely missed signiﬁcance
(P ¼ 0.052) in a multivariate model with the same covariates
(adjusted r
2 ¼ 0.281 for overall model). Surprisingly, NT-proBNP
as a covariate did not reach signiﬁcance in these models.
As NT-proBNP is considered a valuable biomarker for the diag-
nosis of HFnEFESC,
4 we compared GDF-15 with NT-proBNP for
the discrimination of HFnEFESC from healthy controls. ROC
curves for both markers were very similar (Figure 5A) with an
AUC of 0.882 (0.842; 0.922) for NT-proBNP and 0.891 (0.850;
0.932) for GDF-15 (P ¼ 0.37), while the combination of both
markers exhibited a signiﬁcantly larger AUC of 0.942 (0.912;
0.972) compared with NT-proBNP (P , 0.01) or GDF-15 (P ,
0.05) alone. For cut-off levels of 1.16 ng/mL (GDF-15) and
199 ng/L (NT-proBNP), the respective sum of sensitivity and speci-
ﬁcity was maximal. A cut-off value of 1.20 ng/mL has been
Figure 1 Growth differentiation factor 15 levels in systolic
heart failure, HFnEFESC and controls. Broken line denotes rec-
ommended cut-off of 1.20 ng/mL.
Figure 3 Growth differentiation factor 15 levels across three
strata of E/e ´, P , 0.001 for trend by Jonckheere–Terpstra.
Broken line denotes recommended cut-off of 1.20 ng/mL.
Figure 2 Growth differentiation factor 15 levels across grades
of diastolic dysfunction. Grades 2 and 3 were grouped, as only
very few subjects had Grade 3 diastolic dysfunction, P , 0.001
for trend by Jonckheere–Terpstra. Broken line denotes rec-
ommended cut-off of 1.20 ng/mL.
Figure 4 Scatterplot for E/e ´ and log (growth differentiation
factor 15) showing a moderately strong linear correlation
within the normal to high-normal range of E/e ´.
R. Stahrenberg et al. 1312proposed for GDF-15 for a diagnosis of HFrEF.
15 At this value, sen-
sitivity reached 81.7% and speciﬁcity 85.5% with an odds ratio
(OR) of 18.1 for having HFnEFESC. Sinilarly, an NT-proBNP
.220 ng/L is recommended for a positive diagnosis of HFnEFESC,
4
which gives a sensitivity of 65.1%, a speciﬁcity of 96.8% and an OR
of 46, respectively.
Because the utilization of NT-proBNP in the ESC algorithm for
the diagnosis of HFnEFESC would be expected to give this marker
an advantage over GDF-15, we used a different scheme to classify
subjects as HFnEFNew, which did not employ NT-proBNP (see the
section Methods). Eighty-ﬁve subjects had HFnEFNew. Overall,
49.3% of HFnEFESC subjects also fulﬁlled the HFnEFNew criteria,
while 82.4% of HFnEFNew subjects had HFnEFESC. Six minute
walk distance was 418 m (332 m; 504 m) in HFnEFNew. These
ﬁgures are consistent with the notion that echocardiographic cri-
teria for HFnEFNew indicate elevated ﬁlling pressures at the time
of echocardiography and may therefore select a more severely
affected subgroup of HFnEF patients.
Figure 5B illustrates that the AUC of GDF-15 for detecting
HFnEFNew was clearly higher than for NT-proBNP [0.904 (0.857;
0.951) vs. 0.859 (0.805; 0.913)], although this difference did not
reach statistical signiﬁcance (P ¼ 0.10). The combination of both
markers resulted in an AUC of 0.935 (0.892; 0.977), which was sig-
niﬁcantly higher than for NT-proBNP alone (P , 0.01) but not for
GDF-15 alone (P ¼ 0.12). Optimal cut-off levels in the above
sense for the individual markers were 1.16 ng/mL for GDF-15 and
200.7 ng/L for NT-proBNP. The combined presence of a GDF-15
.1.16 ng/mL and NT-proBNP .200.7 ng/L resulted in a sensitivity
of 56.6% and a speciﬁcity of 98.9% for detecting HFnEFNew. For the
proposed cut-off values of 220 and 120 ng/L for NT-proBNP, we
identiﬁed analogous values for GDF-15 with equal sensitivity (speci-
ﬁcity) and compared the corresponding speciﬁcity (or sensitivity,
respectively) at these values. Classiﬁcation at the identiﬁed cut-offs
was better for GDF-15 than for NT-proBNP (Table 2).
Discussion
Our study has the following three main ﬁndings.
(i) Growth differentiation factor 15 plasma levels are elevated in
HFnEFESC patients and comparable to HFrEF.
(ii) Growth differentiation factor 15 levels correlate with multiple
echocardiographic markers of diastolic function and are inde-
pendently associated with a worse 6 min walk test perform-
ance as well as a lower SF-36 physical score.
(iii) Growth differentiation factor 15 is at least as good as
NT-proBNP for the detection of HFnEF and the combination
of both markers is better than NT-proBNP alone.
Figure 5 ROC curves for growth differentiation factor 15, NT-proBNP or their combination for discrimination of (A) HFnEFESC from con-
trols or (B) HFnEFNew from controls.
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Table 2 Comparative diagnostic properties of growth
differentiation factor 15 and NT-proBNP for HFnEFNew
NT-proBNP GDF-15
Speciﬁcity ﬁxed
Cut-off value 220 ng/L
a 1.51 ng/mL
Sensitivity (%) 55 61
Speciﬁcity (%) 97 97
Precision (%) 84 86
Odds ratio 36.7 47.8
Sensitivity ﬁxed
Cut-off value 120 ng/L
a 1.28 ng/mL
Sensitivity (%) 74 74
Speciﬁcity (%) 80 90
Precision (%) 78 86
Odds ratio 10.9 27.6
aRecommended by ESC guidelines
4 to rule in or out HFnEFESC.
GFD-15 in HFnEF 1313The absolute values of GDF-15 in our cohort are in accordance
with the published data: GDF-15 concentrations in HFrEF are sig-
niﬁcantly higher than in healthy elderly controls and the pro-
portion of patients above the proposed cut-off of 1.20 ng/mL as
well as the median value are comparable to data reported by
Kempf et al.
10 This is in spite of our cohort being comparatively
stable outpatients, as evidenced by a median LVEF of 45% and
6 min walk distance of 463 m. In our healthy control group, 86%
of individuals had a GDF-15 value 1.20 ng/mL, similarly close to
published data showing 1.20 ng/mL to be the 90th percentile for
healthy elderly controls.
15 In HFnEFESC, GDF-15 was higher than
in controls but not signiﬁcantly lower than in HFrEF. In multivariate
analysis, presence of HFnEFESC (as well as HFrEF) was indepen-
dently associated with a higher GDF-15 level. Whether GDF-15
levels in HFnEF are indicative of an adverse prognosis, as has
been described for HFrEF and other cardiovascular diseases, has
not been investigated thus far.
Growth differentiation factor 15 is considered a relatively global
and non-speciﬁc marker of risk, as it is also strongly elevated in
other conditions such as malignant or haematological diseases.
23,24
On the other hand, GDF-15 has recently been shown to be pre-
dictive of the presence of any cardiovascular disease, additive to
an established clinical risk score in an elderly population-based
cohort.
25 It is therefore noteworthy that we found rather
strong—considering the epidemiological setting—associations of
GDF-15 with several echocardiographic parameters, strengthening
the usefulness of GDF-15 as an indicator of cardiac status. More-
over, it is interesting that a signiﬁcant correlation between
GDF-15 and structural and functional indicators of diastolic func-
tion such as LVMI, LAVI or E/e ´ was observed. Also, GDF-15
increased with impairment in diastolic function. These data
suggest that GDF-15 might be a marker indicative to some
extent of diastolic function. Increased GDF-15 expression has
been shown in animal models of hypertrophic cardiomyopathy
and load-induced left ventricular hypertrophy,
8 thus providing
experimental support for our observations. Oxidative stress
through uncoupling of cardiac nitric oxide synthase has recently
been shown to induce diastolic dysfunction in an animal model
26
while GDF-15 expression has been shown to be increased in car-
diomyocytes by oxidative stress.
9,27 In this respect, GDF-15 levels
may also partly represent an underlying pathophysiological mech-
anism for diastolic dysfunction. Our data also suggest that
GDF-15 may potentially be an indicator of disease severity in
HFnEF, given its reasonable properties for detecting patients with
elevated ﬁlling pressures (see below) and correlations with
parameters indicative of acutely or chronically elevated ﬁlling
pressures (i.e. E/e ´ and LAVI) and backwards failure (i.e. estimated
right ventricular systolic pressure). The observation that
higher GDF-15 levels were independently associated with
physical impairment on multivariate analysis as assessed by 6 min
walk distance and the SF-36 physical function scale supports this
theory.
When we compared the discriminatory ability of GDF-15 for
differentiating HFnEFESC from healthy controls to that of
NT-proBNP, to indirectly assess its diagnostic properties, we
found it quite remarkable that the properties of GDF-15 were
very similar to those of NT-proBNP. The inclusion of NT-proBNP
for the diagnosis of HFnEFESC would imply a strong methodological
bias towards a better discriminatory ability of NT-proBNP. We
therefore used a second classiﬁcation (termed HFnEFNew)—
which was independent from NT-proBNP—to identify CHF
patients with normal LVEF and elevated left ventricular ﬁlling press-
ures according to the guideline-recommended echocardiographic
criteria.
17 Discriminatory properties of GDF-15 for differentiating
these HFnEFNew patients from controls clearly tended to be
superior to those of NT-proBNP. While exact numbers for
AUC, sensitivity and speciﬁcity cannot be relied upon for clinical
purposes due to the design of our study, the direct comparison
suggests that GDF-15 might in fact be an alternative to
NT-proBNP, although further validation in other cohorts will be
necessary. Combining both biomarkers may be even more attrac-
tive
7 because GDF-15 may be indicative of pathophysiological pro-
cesses different from NT-proBNP, such as inﬂammation.
23 In fact,
the AUC for the combination of both markers was signiﬁcantly
higher than for NT-proBNP for both HFnEFESC and HFnEFNew,
although the combination was not signiﬁcantly superior to
GDF-15 for the latter. Therefore, future trials should speciﬁcally
address whether the combination of NT-proBNP and GDF-15
for the diagnosis of HFnEF really gives incremental value or
whether one of the two markers can be used in isolation.
Ideally, these trials would validate both markers prospectively
against invasive haemodynamic data as a gold standard, which
would also offer the opportunity to compare their values against
currently recommended echocardiographic criteria.
Considering the potential future use of GDF-15 as a marker in
HFnEF it may be reassuring that the optimal discriminatory
cut-off in our cohort of 1.16 ng/L (both for HFnEFESC as well as
HFnEFNew) is very close to the published value of 1.20 ng/L for
HFrEF. Similarly, our observation of an optimal cut-off value for
NT-proBNP of 200.7 ng/L to diagnose HFnEFNew and the high
speciﬁcity of 97% at the recommended cut-off of 220 ng/L actually
validates current ESC recommendations for the use of natriuretic
peptides in the diagnosis of HFnEFESC. These values were largely
derived from two small invasive studies.
28,29 Our data show that
the discriminatory properties of NT-proBNP are very similar in
our cohort of patients with non-invasive, i.e. echocardiographic,
evidence of elevated ﬁlling pressures, underlining the usefulness
of NT-proBNP
30 as recommended currently, until novel markers
such as GDF-15 or others
31 have been further validated individu-
ally or in combination.
Although GDF-15 may be superior to NT-proBNP for the diag-
nosis of HFnEFNew (and similar for the diagnosis of HFnEFESC), its
diagnostic properties are far from perfect. We would therefore
consider the search for a biomarker for HFnEF to be ongoing.
Also, considering the use of such a biomarker in the clinical
setting, it would optimally distinguish HFnEF from HFrEF and
other causes of exertional dyspnoea, of which the former is
neither true for GDF-15 nor for NT-proBNP while the latter
cannot be tested in our cohort.
With regards to limitations of our study, we would like to stress
that the diagnostic properties reported are solely for comparative
purposes. Differentiating apparently healthy elderly individuals
from patients presenting with the syndrome of heart failure using
additional biomarker testing is rarely a clinical issue. The number
R. Stahrenberg et al. 1314of CHF patients in our cohort was relatively small and analyses are
therefore of limited statistical power. On the other hand, all
patients were comprehensively characterized by echocardiogra-
phy, making a classiﬁcation of HFnEFESC or HFnEFNew possible.
Our interpretation that GDF-15 is a marker which is at least as
good as NT-proBNP is formally somewhat imprecise, as there
were no criteria for non-inferiority prospectively deﬁned.
Although an invasive conﬁrmation and quantiﬁcation of diastolic
dysfunction would have been preferable, such an approach
would not have been feasible in a medium-scale population-based
study like DIAST-CHF. It is striking that of all the patients with a
history or signs and symptoms of CHF and with an LVEF .50%,
only 55.4% met the criteria for the diagnosis of HFnEFESC. While
beyond the scope of this paper, the study of the remaining patients
with CHF and LVEF .50% will help to facilitate a better under-
standing of HFnEF and the value of the ESC criteria. Preliminary
analyses suggest that patients meeting ESC criteria are considerably
more symptomatic, suggesting that these criteria are in fact more
speciﬁc for the identiﬁcation of truly symptomatic HFnEF.
Conclusions
The novel cardiovascular risk marker GDF-15 is elevated in
patients with HFnEF. Growth differentiation factor 15 levels corre-
late with echocardiographic markers of diastolic function and elev-
ated ﬁlling pressures. They are independently associated with
exercise capacity and physical aspects of quality of life. Discrimina-
tory properties for differentiating HFnEF from healthy individuals
are at least as good as those of NT-proBNP. These results merit
further investigation of the value of GDF-15 for diagnosis, prognos-
tication and therapy guidance in diastolic heart failure.
Supplementary material
Supplementary material is available at European Journal of Heart
Failure online.
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